Operating data: The company achieved total operating income of 227 million yuan in 2013, an increase of 117.04%; net profit attributable to shareholders of listed companies was 139 million yuan, an increase of 1743.15% over the previous year, corresponding to earnings of 0.55 yuan per share. Net profit is expected to increase by 636.0-682.08% from January to March 2014, and is expected to turn 10 to 0.8. Sales of traditional main products are improving. In 2013, the company stepped up its marketing efforts and brand promotion, placed leading product advertisements on CCTV channels 2 and 3, and carried out a series of terminal promotion activities, continuing to maintain sales growth of leading products such as Double Product Dispersion and Sensitive Film. At the same time, it adhered to a multi-product development strategy, increased efforts to promote new products, strengthened weak market development, and effectively created new profit growth points, and the brand image was enhanced. The acquisition of Sands Pharmaceuticals ushered in an inflection point in performance and enhanced core competitiveness. While adhering to the development of its main business, the company acquired the remaining 64.47% of Jinsha Pharmaceutical's shares in due course in November. After taking wholly-owned ownership of Jinsha Pharmaceutical, the company's product line expanded from medicine for colds to the field of traditional Chinese medicine for bone injuries; in terms of channels, retail markets in South China and southwest China entered hospital terminals in all provinces and cities across the country, creating a win-win and mutually beneficial situation, greatly improving the company's core competitiveness and profitability. During the reporting period, revenue in 2013 increased by 117.04%, gross margin increased by 7.18 percentage points, while sales, management and financial expense ratios decreased by 6.62, 7.10, and 1.21 percentage points year on year, respectively, and net profit surged 1743.15 percentage points. In 2014, the plum blossom planting base is expected to expand production from 3,000 mu to 5,000 mu. The company will continue to work with universities and research institutes such as South China University of Technology, Jinan University, and South China Agricultural University to cultivate and develop plum tree resources and promote research on key technologies for large-scale production of high-purity natural dextradiol (natural ice flakes) in an orderly manner; aim to expand the planting of 2,000 acres of plum blossom base on the basis of the original 3,000-acre planting base, and complete the construction of an excellent plum blossom seed nursery with plum blossom cultivation base to further develop the construction work of plum extract workshops; to include the 2015 new Pharmacopoeia, the quality standards for doublepharyngeal ventilation and natural dextron dominated by the company Made according to quality standards Preliminary preparation. Profit forecasting and valuation. We expect the company's EPS in 2014-2016 to be 0.58 yuan/0.75 yuan/1.08 yuan respectively, corresponding to 39.3 times/30.6 times/21.1 times PE. The plum blossom planting and active ingredient extraction project has been included in the Guangdong Sailing Plan. It is a key project for the province's second greening and green GDP. It has received full support from all levels of government and local farmers in Guangdong Province, and has enjoyed many benefits such as VAT and income tax relief. There is huge potential for value-adding/growth. It maintains a “buy” rating, and the target price has been raised to 32.4 yuan.